Gujarat Kidney lists at Rs 120 on the National Stock Exchange, which is a premium of 5.26% to the issue price, Rs 114.
Gujarat Kidney IPO: Key details
The company raised Rs 250.80 crores by going public. The issue was entirely a fresh issue of 2.20 crore shares. The IPO bidding started on December 22 and ended on December 24. The allotment for IPO shares was finalised on December 26. The company kept the issue price at Rs 114 per equity share. The IPO was subscribed by a total of 5.21 times. The retailers booked the issue 19.04 times and NIIs 5.73 times. However, the QIBs remained a bit reluctant, subscribing to the IPO 1.06 times.
Gujarat Kidney IPO: GMP
The shares of Gujarat Kidney & Super Speciality were changing hands at a premium of over 1.3% a day ahead of listing. The stock was trading at Rs 115.5.
Gujarat Kidney IPO: Lot size
A retail applicant needs to apply for a minimum of one lot of 128 shares, amounting to Rs 14,592. The lot size investment for a small non-institutional investor (NII) is 14 lots of 1,792 shares, aggregating to Rs 2 lakh, and for a big NII, it is 69 lots of 8,832 shares, totalling to Rs 10 lakh.
Gujarat Kidney IPO: Book runner and registrar
Nirbhay Capital Services worked as the book-running lead manager of the issue, and MUFG Intime India is the registrar for the IPO.
Gujarat Kidney IPO: Objectives of the issue
The company will be using Rs 77 crore for the acquisition of Parekhs Hospital at Ahmedabad, while it will be using Rs 12.40 crore for the payment of the already acquired ‘Ashwini Medical Centre’. Also, the company will be using Rs 30 crore for funding capital expenditure towards setting up a new hospital in Vadodara. The raised funding will also be used for the payment of certain borrowings and purchasing robotic machines for hospitals.
About Gujarat Kidney and Super Speciality
Incorporated in 2019, Gujarat Kidney and Super Speciality specialises in providing multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat, India.
The company operates seven multispeciality hospitals and four pharmacies with a total bed capacity of 490 beds, an approved capacity of 455 beds, and an operational capacity of 340 beds.